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Osteoradionecrosis of jawsAbstract Osteoradionecrosis of jaws (ORNJ) is a serious complication of radiotherapy for patients
with head and neck cancer. As of yet, no universally accepted treatment exists for this chronic
pathologic condition. It has been shown that ultrasound is an effective, noninvasive adjunctive ther-
apy in ORNJ, as ultrasound can result in the increase of angiogenesis and bone production, which
are essential for ORNJ healing. Recently, low-frequency ultrasound has been demonstrated to
enhance the transdermal delivery of macromolecules and hydrophilic drugs (low-frequency
sonophoresis, LFS). As a biological macromolecule, basic ﬁbroblast growth factor (bFGF) also
has potential osteoinductive and angiogenic properties. Herein, we present a hypothesis that
LFS-mediated transdermal bFGF delivery is capable of improving the healing of ORNJ and will
be a new effective adjunctive therapy to surgery. This treatment combines low-frequency ultrasound
with bFGF to respectively promote vascularly compromised bone and soft tissue wound healing,
and is expected to be more effective than ultrasound therapy alone.
ª 2014 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
As one of the worst complications of radiotherapy,
osteoradionecrosis of jaws (ORNJ) is a serious delayed injury,characterized by bone tissue necrosis and failure to heal for
3–6 months [1]. Surgery is the main treatment for ORNJ at
present. However, due to no clear boundaries between living
bone and sequestrum, it is very difﬁcult to completely remove
all the dead bone through surgery, which often leads to325027,
10 Z. Zhou et al.prolonged unhealed wounds and subsequent multiple surg-
eries. To completely block the progression of ORNJ, surgery
combined with adjuvant therapies is regarded as the standard
treatment [2]. Previously, hyperbaric oxygen (HBO) was an
important adjuvant to surgery in ORNJ. The rationale for
using HBO is that the intermittent elevation of tissue oxygen
tension stimulates collagen synthesis and ﬁbroblastic
proliferation, promotes the growth of new capillaries, and
enhances the phagocytic ability of leukocytes [3]. However,
some controversy of its efﬁcacy, lack of availability, and high
price are potential disadvantages [4–6].
Ultrasound has been proposed as a conservative treatment
for ORNJ and alternative to hyperbaric oxygen therapy
(HBOT) [7], as it is economical, readily available, and user-
friendly. It has been shown that ultrasound is capable of
increasing angiogenesis and stimulating collagen and bone
production, which, in turn, effectively improves the metabolic
activity of the irradiated bone [8,9]. Apart from its thera-
peutical effect, ultrasound can be used as a physical enhancer
for transdermal drug delivery (sonophoresis). Low-frequency
sonophoresis (LFS, 20–100 kHz), in particular, is up to three
orders of magnitude more effective in inducing transdermal
transport than high-frequency ultrasound [10] and has shown
promise in delivering both macromolecules and hydrophilic
permeants such as insulin [11,12], erythropoietin [13], heparin
[14], and bovine serum albumin [15], along with other hor-
mones [16] and oligoneucleotides [17]. Affected by low-fre-
quency ultrasound, cavitation bubbles grow and collapse
near the surface of the stratum corneum (SC), which allows
the passive permeation of only small lipophilic molecules
across the skin, leading to the formation of microjet, ultimately
disrupting SC lipid bilayers and increasing skin permeability
[18]. However, these structural changes in the SC return to
normal after a period of time [10,19].
Hypothesis/idea
We creatively put forward a hypothesis that the use of LFS for
transdermal basic ﬁbroblast growth factor (bFGF) delivery
can improve the healing of ORNJ and will be a new effective
adjunct to surgery. The process involves two phases: low-fre-
quency, low-intensity ultrasound (frequency of 45 kHz, inten-
sity of 30 mW/cm2, pulse wave) is applied as a pretreatment
to the irradiated skin after major jaw surgery, and bFGF aque-
ous solution (600 ng/ml) is then evenly smeared on the ultra-
sound-irradiated area, which can passively deliver across the
skin barrier and deep into soft tissue. This treatment regimen
is given once daily, 20 min each time for 20 days .On the one
hand, low-frequency ultrasound increases revascularization
and bone regeneration to resurrect the hypoxic–hypovascu-
lar–hypocellular irradiated bone. On the other hand, bFGF
delivered promotes angiogenesis, thereby improving vessel-
compromised irradiated soft tissue wound healing and pre-
venting the impaired healing from causing a prolonged mor-
bidity of ﬁstula, wound dehiscence, skin ﬂap reconstructive
failure, and skin necrosis.
Evaluation of the hypothesis/idea
In irradiated bone repair, improving osteogenesis and angio-
genesis is an important goal. Low-frequency ultrasound has
a capacity to promote ﬁbroblast and osteoblast proliferationand protein production to a similar or an even greater extent
than traditional 1-MHz ultrasound, and is capable of deeper
bone penetration [20]. The mechanism associated with bone
formation by low-frequency ultrasound stimulation may be
increasing the ratio of osteoprotegerin (OPG) to the receptor
activator of nuclear factor kappa B ligand (RANKL) in osteo-
blasts, because the former is osteogenic and RANKL activates
osteoclast formation [21]. Moreover, ultrasound in the kilo-
hertz range stimulates nitric oxide and prostaglandin produc-
tion by human osteoblasts [22]. Likewise, it has been noted
that low-frequency ultrasound increases the synthesis of angio-
genesis-related cytokines such as vascular endothelial growth
factor (VEGF), bFGF, and interleukin 8 (IL-8) [23].
Reestablished or increased blood ﬂow in the ORNJ site
improves cell delivery and tissue oxygenation, and so can heal
osteoradionecrotic bone by countering the negative effects of
hypoxia, hypocellularity, and hypovascularity [24].
The potent angiogenic growth factor bFGF plays pivotal
roles during wounds healing [25]. BFGF can regulate the
migration and replication of endothelial, epithelial, and ﬁbrob-
last cells, which are responsible for neovascularization, col-
lagen production, and epithelialization [26]. It was found
that decreased local levels of bFGF in the skin played a major
role in the delayed healing of irradiated wounds [27,28]. Thus,
supplemental bFGF may be important for irradiated post-
surgical soft tissue healing. It has been shown that the use of
bFGF prior to bone grafting improved vascularity in the
irradiated soft tissue bed, which reduced the risk of bone
graft failure [29], and that intravenous bFGF improved
random skin ﬂap viability and increased skin ﬂap tolerance
to irradiation [27,30].
Low-frequency ultrasound and bFGF have separately
showed resistance to irradiation-induced bone and soft tissue
injury. However, for transdermal bFGF delivery by LFS to
be effective, bFGF must be able to penetrate the skin barrier
and deep into soft tissues. LFS is competent to achieve the
transdermal delivery of large molecules of molecular weight
up to 150 kDa [31]. bFGF is a hydrophilic protein with a
molecular weight of approximately 18 kDa. In addition, earlier
studies have demonstrated the potential of LFS to treat
chronic soft tissue lesions [32–34]. Reasonably, bFGF deliv-
ered by LFS is supposed to be able to overcome the SC barrier
into the deeper layers of the skin and remain intact in vivo to
exert its pharmacological effect. Given that the action of ultra-
sound on drugs may cause the degradation of molecules to
occur, the choice of the pretreatment protocol, rather than a
simultaneous protocol, avoids the loss of activity of the thera-
peutic compound [31]. LFS also allows for controlled-release
proﬁles to lengthen effective drug concentration, without con-
cerning the short half-life of bFGF [35].
In the process of the transdermal delivery of bFGF, the
safety of LFS should be evaluated rigorously. The effect of
LFS on animal models and cell lines has shown that the use
of low ultrasound intensities causes no changes in skin pathol-
ogy and cell viability [10,36]. Moreover, usually no serious
adverse reactions generated by LFS have been reported in
clinical studies, with the most common side effect being mild
erythema, due to the use of low intensities that generate neg-
ligible temperature variations and minimize thermal effects
on tissues [37,38]. Therefore, LFS with low intensity used to
enhance the transdermal delivery of bFGF is safe, although
more convincing evidence is needed.
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Transdermal bFGF delivery using LFS will be beneﬁcial in
managing hypoxia, hypocellularity, and hypovascularity of
ORNJ, probably through the following three ways: (1) pro-
moting cell proliferation improves hypocellularity, (2) increas-
ing collagen and non-collagen protein synthesis enhances bone
regeneration and wound healing, and (3) promoting angio-
genesis solves the problem of hypoxia and hypovascularity.
Besides bFGF, growth factors including transforming growth
factor b (TGF-b), platelet-derived growth factor (PDGF), epi-
dermal growth factor (EGF), and VEGF could also be deliv-
ered through the skin for irradiated soft tissue healing.Overview Box
First question: What do we already know about the
subject?
1. ORNJ is considered an ischemic necrosis with the
exposed bone characterized by hypocellularity, hypoxia,
and hypovascularity.
2. Transdermal bFGF delivery using LFS has a capac-
ity to promote cell proliferation, increase collagen and
non-collagen protein synthesis, and stimulate
angiogenesis.
Second question: What does your proposed theory add to
the current knowledge available, and what beneﬁts does it
have?
Transdermal bFGF delivery using LFS can counter
radiation-induced negative effects and accelerate vascu-
larly compromised bone and soft tissue wound healing;
thus, it may be a novel potentially adjunct treatment in
ORNJ.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
Transdermal bFGF delivery by LFS, as an interfering
measure, can be performed in the established ORNJ ani-
mal model.
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